SCYNEXIS, Inc. to Report Phase 2a Study of SCY-635 for Treatment of HCV at American Association for Study of Liver Diseases  
11/5/2012 9:17:07 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts. The Phase 2a study tested SCY-635 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a difficult to treat population of HCV genotype 1 patients.